Notice of Extraordinary General Meeting in DexTech Medical AB

Dextech Medical AB's shareholders are welcome to attend the Extraordinary General Meeting which will take place on Wednesday, May 11, 2022 at 10.00 in IVA's conference center, Royal. Academy of Engineering Sciences, Grev Turegatan 16, Stockholm. Admission to the meeting begins at 9.30.

Registration and registration

Shareholders who wish to participate in the Extraordinary General Meeting must

• be entered in the share register kept by Euroclear Sweden AB on Tuesday, May 3, 2022 and

• register with the company no later than Friday, May 6, 2022. Registration can be made via e-mail ([email protected]) or in writing to:

Dextech Medical AB

Extraordinary general meeting,

Box 389

751 06 Uppsala.

The notification must state the full name, personal or organization number, shareholding, address, telephone number during the day and, if applicable, information on representatives or advisors (maximum 2) must be provided. The application must, if applicable, be accompanied by proxies, registration certificates and other authorization documents.

The Extraordinary General Meeting will be held in Swedish.

Nominee-registered shares

Shareholders who have their shares nominee-registered, through a bank or other nominee, must, in order to be entitled to participate in the Annual General Meeting, temporarily register the shares in their own name with Euroclear Sweden AB. Such re-registration must be completed no later than Tuesday, May 3, 2022, which means that shareholders who wish such re-registration must notify the nominee in time before the mentioned date.

Agents etc.

If shareholders are to be represented by a proxy, the proxy must have a written, dated and signed proxy for the meeting for the shareholder. The power of attorney may not be older than one year, unless a longer period of validity (however, a maximum of five years) has been stated on the power of attorney. If the power of attorney has been issued by a legal entity, the representative must also have the current registration certificate or equivalent authorization documents for the legal entity. To facilitate access, a copy of the power of attorney and other authorization documents should be attached to the notification to the meeting. Proxy forms are kept available on the company's website www.dextechmedical.com and are sent by post to shareholders who contact the company and state their address.

Agenda

 1. Election of chairman of the meeting.

 2. Establishment and approval of the ballot paper

 3. Presentation and approval of the agenda.

 4. Election of one or two adjusting persons to adjust the minutes together with the chairman.

 5. Examination of whether the meeting has been duly convened.

 6. Determination of the number of board members.

 7. Determination of fees to the Board.

 8. Election of board members.

 9. Closing of the meeting.

Decision proposal in brief

Determination of the number of board members (item 6)

Shareholders representing just over 60% of the total number of shares in the company have proposed that the Board have six (6) ordinary members without deputies.

Determination of fees to the Board (item 7)

Shareholders representing just over 60% of the total number of shares in the company have proposed that fees be paid to the Chairman of the Board of SEK 200,000 calculated on a calendar year basis and that fees not be paid to other members.

Election of a board member (item 8)

Shareholders representing just over 60% of the total number of shares in the company have proposed that Andreas Segerros be elected as a new board member, and that Anders Holmberg, Svante Wadman, Per Asplund, Rolf Eriksson and Sten Nilsson be re-elected as board members.

Andreas Segerros (born 1960) has a: Master of Business Administration (MBA), International Management and Finance, Uppsala University; and Master of Science (MSC), Organic Chemistry and Chemical Engineering, KTH Stockholm; and a Bachelor of Administration (BA DIHM). IHM Stockholm.

He has a long and solid experience with executive positions in the international pharmaceutical industry in Europe, the USA and Japan, among others. within Pharmacia Corporation, USA, Sunshine Capital A / S, Denmark and Ferring Pharmaceuticals S.A., Switzerland.

__________________________

Stockholm in April 2022

THE BOARD OF DIRECTORS

For further information about DexTech, please contact:

Gösta Lundgren – CFO

DexTech Medical AB

Phone: +46 (0) 707104788

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to outlicense the respective drug candidate no later than after the completion of a phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.